A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Cell

• Publication date

  2013-08-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccr.2013.07.008PMID 23948298PMCID PMC3773329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sequence analysis of mutations and translocations across breast cancer subtypes

  2012cited by this paper
• An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.

  2012cited by this paper
• Dissecting the heterogeneity of triple-negative breast cancer.

  2012cited by this paper
• Faculty Opinions recommendation of Most random gene expression signatures are significantly associated with breast cancer outcome.

  2012cited by this paper
• Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo

  2012influential reference
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• The clonal and mutational evolution spectrum of primary triple-negative breast cancers

  2012cited by this paper
• Cancer stem cell definitions and terminology: the devil is in the details

  2012cited by this paper
• HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers.

  2012cited by this paper
• The landscape of cancer genes and mutational processes in breast cancer

  2012cited by this paper
• Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma

  2011cited by this paper
• Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function

  2010cited by this paper
• Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation

  2010cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• Will the ubiquitin system furnish as many drug targets as protein kinases?

  2010cited by this paper
• Therapeutic strategies within the ubiquitin proteasome system

  2010cited by this paper
• Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.

  2010cited by this paper
• Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice.

  2010cited by this paper
• A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

  2010cited by this paper
• Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction

  2010cited by this paper
• Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

  2010cited by this paper
• Reactome: a database of reactions, pathways and biological processes

  2010cited by this paper
• Cytoscape: a community-based framework for network modeling.

  2009cited by this paper
• Identification of selective inhibitors of cancer stem cells by high-throughput screening.

  2009cited by this paper
• High Throughput Screening

  2009cited by this paper
• KEGG for representation and analysis of molecular networks involving diseases and drugs

  2009cited by this paper
• A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.

  2009cited by this paper
• Do 'basal-like' breast cancers really exist?

  2009cited by this paper
• Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer

  2009cited by this paper
• The humoral immune system has a key prognostic impact in node-negative breast cancer.

  2008influential reference
• An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer.

  2008cited by this paper
• Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

  2008cited by this paper
• WikiPathways: Pathway Editing for the People

  2008cited by this paper
• Triple-negative breast cancer.

  2008cited by this paper
• Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

  2007cited by this paper
• Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.

  2007cited by this paper
• A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience

  2007cited by this paper
• Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer.

  2007cited by this paper
• BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

  2007cited by this paper
• X chromosomal abnormalities in basal-like human breast cancer.

  2006cited by this paper
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

  2006cited by this paper
• Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

  2005cited by this paper
• Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

  2005cited by this paper
• Prospective identification of tumorigenic breast cancer cells

  2003cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

  1999cited by this paper

• Therapeutic potential of liposome@azoramide in cancer by suppressing oxidative phosphorylation.

  2026cites this paper
• The Study of Metabolic Characteristics of Breast Cancer Metastases Using Fluorescence Lifetime Imaging Microscopy

  2025cites this paper
• Extracellular Vesicle–Based Biohybrid Enabling Synergistic Anti‐Oxidative Stress and Anti‐Inflammation for Targeted Therapy of Acute Kidney Injury

  2025cites this paper
• An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant Chemotherapy.

  2025cites this paper
• Drug repurposing identifies proteasome inhibitors as antiproliferative agents counteracting inflammation-driven chemoresistance in triple-negative breast cancer organoids.

  2025cites this paper
• Proteostasis Disruption by Proteasome Inhibitor MG132 and Propolin G Induces ER Stress‐ and Autophagy‐Mediated Apoptosis in Breast Cancer

  2025influential citation
• Loss of correlated proteasomal subunit expression selectively promotes the 20SHigh state which underlies luminal breast tumorigenicity

  2025cites this paper
• Nidogen-1 suppresses cell proliferation, migration, and glycolysis via integrin β1-mediated HIF-1α downregulation in triple-negative breast cancer

  2025cites this paper
• HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer

  2024cites this paper
• Multifaceted impact of HIV inhibitor dapivirine on triple negative breast cancer cells reveals potential entities as targets for novel therapy

  2024cites this paper
• Nitro-fatty acids: promising agents for the development of new cancer therapeutics.

  2024cites this paper
• Inhibition of proteolytic and ATPase activities of the proteasome by the BTK inhibitor CGI-1746

  2024cites this paper
• Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer

  2024cites this paper
• Understanding the Transcription Factor NFE2L1/NRF1 from the Perspective of Hallmarks of Cancer

  2024cites this paper
• Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts

  2024cites this paper
• Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer.

  2024cites this paper
• Discovery of the First Potent DYRK2 Proteolysis Targeting Chimera Degraders.

  2024cites this paper
• Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

  2024cites this paper
• Cancer associated fibroblasts mitigate the efficacy of the combination of chemotherapy and BCL-xL targeting in triple negative breast cancer cells

  2024cites this paper
• An impaired ubiquitin-proteasome system increases APOBEC3A abundance

  2023cites this paper
• Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide

  2023cites this paper
• Genome-wide siRNA screens identify RBBP9 function as a potential target in Fanconi anaemia-deficient head-and-neck squamous cell carcinoma

  2023cites this paper
• Evaluation of the NRF1-proteasome axis as a therapeutic target in breast cancer

  2023cites this paper
• Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities

  2023cites this paper
• Depleting the 19S proteasome regulatory PSMD1 subunit as a cancer therapy strategy

  2023cites this paper
• Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs

  2023cites this paper
• Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers

  2023cites this paper
• Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models

  2022cites this paper
• New anti-cancer explorations based on metal ions

  2022cites this paper
• Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel

  2022cites this paper
• ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin

  2022cites this paper
• Sustained oncogenic signaling in the cytostatic state enables targeting of non-proliferating persistent cancer cells.

  2022cites this paper
• Sem1/DSS1 accelerates ATP-dependent substrate unfolding by the proteasome through a conformation-dependent intercomplex contact

  2022cites this paper
• Determination of the Effectiveness of a Novel Liposome Formulation of Proteasome Inhibitors

  2022cites this paper
• Comprehensive analysis of gene expression profiles to identify differential prognostic factors of primary and metastatic breast cancer

  2022cites this paper
• Simultaneous proteasome and autophagy inhibition synergistically enhances cytotoxicity of doxorubicin in breast cancer cells

  2022cites this paper
• Proteasome Inhibitors Decrease the Viability of Pulmonary Arterial Smooth Muscle Cells by Restoring Mitofusin-2 Expression under Hypoxic Conditions

  2022cites this paper
• Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis

  2022cites this paper
• MCL-1 is a clinically targetable vulnerability in breast cancer

  2022cites this paper
• Targeting Apoptosis in Cancer

  2022cites this paper
• Roles of CNC Transcription Factors NRF1 and NRF2 in Cancer

  2021cites this paper
• ERK signaling licenses SKN-1A/NRF1 for proteasome production and proteasomal stress resistance

  2021cites this paper
• Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo

  2021cites this paper
• Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.

  2021cites this paper
• Therapeutically Targeting Cancers That Overexpress FOXC1: A Transcriptional Driver of Cell Plasticity, Partial EMT, and Cancer Metastasis

  2021cites this paper
• The transcription factor BACH1 at the crossroads of cancer biology: From epithelial–mesenchymal transition to ferroptosis

  2021cites this paper
• A precision approach to breast cancer treatment based on cell lineage-specific vulnerabilities

  2021cites this paper
• The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents

  2021cites this paper
• LncRNAs associated with glioblastoma: From transcriptional noise to novel regulators with a promising role in therapeutics

  2021cites this paper
• Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function

  2021cites this paper
• Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells.

  2021cites this paper
• Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study

  2021cites this paper
• MIG‐6 is essential for promoting glucose metabolic reprogramming and tumor growth in triple‐negative breast cancer

  2021cites this paper
• Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

  2021cites this paper
• The Functional and Mechanistic Roles of Immunoproteasome Subunits in Cancer

  2021cites this paper
• Interleukin-8-Induced Invasion Assay in Triple-Negative Breast Cancer Cells.

  2020cites this paper
• PROTEASOME INHIBITION ENHANCES THE EFFECT OF BIKDD GENE THERAPY

  2020cites this paper
• Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer

  2020cites this paper
• A bird's eye view of the advanced approaches and strategies for overshadowing triple negative breast cancer.

  2020cites this paper
• The E3 ligase UBR2 regulates cell death under caspase deficiency via Erk/MAPK pathway

  2020cites this paper
• Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.

  2020cites this paper
• Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis

  2020cites this paper
• Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis

  2020cites this paper
• Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives

  2020cites this paper
• Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.

  2020cites this paper
• Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer

  2020cites this paper
• Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens

  2020cites this paper
• Gasdermin E suppresses tumor growth by activating anti-tumor immunity

  2020cites this paper
• Carfilzomib delivery by quinic acid-conjugated nanoparticles: Discrepancy between tumoral drug accumulation and anticancer efficacy in a murine 4T1 orthotopic breast cancer model.

  2020cites this paper
• Mitochondrial metabolism promotes adaptation to proteotoxic stress

  2019cites this paper
• Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis

  2019cites this paper
• The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer

  2019influential citation
• PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer.

  2019cites this paper
• Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.

  2019influential citation
• Overlap between eQTL and QTL associated with production traits and fertility in dairy cattle

  2019cites this paper
• Therapeutic potential of PLK1 inhibition in triple-negative breast cancer

  2019cites this paper
• Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells.

  2019cites this paper
• siRNA Library Screening to Identify Complementary Therapeutic Pairs in Triple-Negative Breast Cancer Cells.

  2019cites this paper
• Evaluation of AAV-mediated delivery of shRNA to target basal-like breast cancer genetic vulnerabilities.

  2019cites this paper
• A cross-species whole genome siRNA screen in suspension-cultured Chinese hamster ovary cells identifies novel engineering targets

  2019cites this paper
• What makes cells move: Requirements and obstacles for leader cells in collective invasion.

  2019cites this paper
• Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes

  2019cites this paper
• Long Non-coding RNAs as Communicators and Mediators Between the Tumor Microenvironment and Cancer Cells

  2019cites this paper
• Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells

  2019cites this paper
• A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability

  2019cites this paper
• Proteostasis in the Endoplasmic Reticulum: Road to Cure

  2019cites this paper
• Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression

  2019influential citation
• Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

  2019influential citation
• Cytidine monophosphate N-acetylneuraminic acid synthetase enhances invasion of human triple-negative breast cancer cells

  2018cites this paper
• The pleiotropic effects of TNFα in breast cancer subtypes is regulated by TNFAIP3/A20

  2018cites this paper
• Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy

  2018cites this paper
• Predicting Methylation from Sequence and Gene Expression Using Deep Learning with Attention

  2018cites this paper
• Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2

  2018influential citation
• Next‐generation proteasome inhibitors for cancer therapy

  2018cites this paper
• O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in Cancer Cells by Stabilizing NRF1

  2018cites this paper
• MCL-1 is a prognostic indicator and drug target in breast cancer

  2018cites this paper
• Applications of RNA Indexes for Precision Oncology in Breast Cancer

  2018cites this paper
• Predictive bioinformatics identifies novel regulators of proliferation in a cancer stem cell model.

  2018influential citation
• cytidine monophosphate N -acetylneuraminic acid synthetase enhances invasion of human triple-negative breast cancer cells

  2018cites this paper
• Proteotoxic stress-induced Nrf1 transcriptional program requires a functional TIP60 complex

  2018cites this paper